Type of anaesthesia used during breast cancer surgery may affect the risk of cancer recurrence

July 14, 2014, University College Dublin

Type of anaesthesia used during breast cancer surgery may affect the risk of cancer recurrence
(Medical Xpress)—Breast cancer is one of the main causes of cancer-related death in women. According to the National Cancer Registry, breast cancer is the most frequently diagnosed form of cancer in Ireland representing 32% of all cancer diagnosis every year.

Each year, in Ireland about 2,600 women are diagnosed with breast and 660 women die from the disease. The deaths are mainly related to the spread of the disease through the bloodstream or lymphatic system to other parts of the body such as the bones, lungs, liver and brain, rather than the primary tumour.

New research findings by University College Dublin scientists published in the British Journal of Anaesthesia indicate that the type of anaesthetic used during surgery could affect the metastatic potential of - that is their ability to spread to other parts of the body.

To conduct the research, the scientists took blood before and after surgery from who had been given different types of anaesthetic and pain relief. Some of the had used standard inhaled general anaesthetics with morphine based pain relief, and others had been anaesthetised using regional (breast numbing) techniques with a single intravenous general anaesthetic called propofol to minimize morphine dosing. In laboratory conditions, breast cancer cells were then exposed to these blood samples.

The scientists found that the blood from patients who had been given standard inhaled general anaesthetics with morphine pain relief reduced a process known as "apoptosis" whereby the body's cells naturally die off. "Apoptosis" is crucial to preventing the metastatic spread of cancer. In contrast, cancer cells exposed to blood from patients who had been given regional anaesthesia and propofol showed a higher rate of apoptosis, or natural death of cancer cells.

In separate research also carried out at University College Dublin and published in this Special Issue of the British Journal of Anaesthesia on Cancer and Anaesthesia, laboratory tests indicate that anaesthetic technique can affect the activity of the body's immune system and its Natural Killer (NK) cells. NK cells are important in the body's resistance to the spread of cancer. Blood from breast cancer patients was exposed to NK cells and cells. The blood from patients who had been given regional anaesthesia and propofol resulted in more Natural Killer cell anti-cancer activity than the blood from patients who received standard inhaled general anaesthetics with morphine .

UCD Professor Donal Buggy, Professor of Anaesthesia at the UCD School of Medicine and Medical Science, University College Dublin, and a Consultant Anaesthesiologist at the Mater Misericordiae University Hospital, who headed-up the research, points out that these laboratory results are not conclusive, and that there is not currently enough evidence to indicate cancer patients should choose one anaesthetic technique over another. However, he is calling for funding for ongoing research to ascertain if changing anaesthetic techniques could ultimately benefit .

Explore further: Stopping the spread of breast cancer

Related Stories

Stopping the spread of breast cancer

June 3, 2014
The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine® scientists have discovered a new pathway that can stop breast cancer cells from ...

Stem cell researcher targets the 'seeds' of breast cancer metastasis

July 11, 2014
For breast cancer patients, the era of personalized medicine may be just around the corner, thanks to recent advances by USC Stem Cell researcher Min Yu and scientists at Massachusetts General Hospital and Harvard Medical ...

Men develop breast cancer, too

July 8, 2014
(HealthDay)—While rare, breast cancer does occur in men and is often diagnosed at a later age and stage than in women, experts say.

Immune cells found near tumours boost breast cancer survival

June 10, 2014
Women with breast cancer are 10 per cent more likely to survive for five years or more if they have certain immune cells near their tumour, according to research published in Annals of Oncology today.

New test predicts the risk of non-hereditary breast cancer

June 27, 2014
A simple blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, even in the absence of a high-risk BRCA1 gene mutation, according to research published in the open ...

Anesthesia technique may reduce breast cancer recurrence and death

October 16, 2013
Breast cancer patients who received the combination of a nerve block with general anesthesia for their breast cancer surgery had less cancer recurrence and were three times less likely to die than those who received only ...

Recommended for you

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers

December 17, 2018
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.